Evidence map›Paper›PMID 25910560›Full record

ArticleThe Kaohsiung journal of medical sciences2015

Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.

Wen-Hung Hsu, Fu-Chen Kuo, Huang-Ming Hu, Ping-I Hsu, Deng-Chyang Wu, Chao-Hung Kuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wen-Hung HsuDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Fu-Chen KuoSchool of Medicine, College of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Huang-Ming HuDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Ping-I HsuDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.
Deng-Chyang WuCenter for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chao-Hung KuoCenter for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: kjh88kmu@gmail.com.
Kaohsiung Medical University · TWE-Da Hospital · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin (IL)-1β is a potent inhibitor of gastric acid secretion and its genetic polymorphism is linked to the severity of reflux esophagitis. Proton-pump inhibitor (PPI) metabolized by P450 2C19 (CYP2C19) is the chief medication in reflux esophagitis treatment. The CYP2C19 genotype may influence the therapeutic effect of PPI for reflux esophagitis. From November 2009 to June 2012, 184 patients were enrolled in this study with endoscopy examination, 8 weeks of esomeprazole treatment, and 20 weeks of follow-up with questionnaire. These patients also received endoscopy examination after 20 weeks. Blood was collected for genetic polymorphism analysis with polymerase chain reaction. After 8 weeks of treatment with esomeprazole, all of these 184 patients had achieved complete symptom relief. However, in the following 12 weeks, 58.70% (108/184) complained of symptom relapse, 45.65% (84/184) patients had persistent esophageal erosion verified by endoscopy, and in total, 76.09% (140/184) patients had treatment failure at the end of 20 weeks. There were no influences between the genetic polymorphisms of CYP2C19 and IL1B to treatment failure (p = 0.896). Therefore, prolonging PPI treatment and further lifestyle modification might be warranted for symptomatic mild esophagitis. There were no relationships between IL-1β and CYP2C19 in the treatment effect in mild reflux esophagitis.

Indexed as

Cytochrome P-450 CYP2C19EsomeprazoleEsophagitis, PepticHumansInterleukin-1betaPolymorphism, GeneticProton Pump InhibitorsSurveys and QuestionnairesTreatment OutcomeCytochrome P-450 CYP2C19EsomeprazoleInterleukin-1betaProton Pump InhibitorsCYP2C19Genetic polymorphismInterleukin-1βProton pump inhibitorReflux esophagitis

Identifiers

PMID25910560
PMCPMC11916253
OpenAlexW2111005088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.